W M Rosenberg
Overview
Explore the profile of W M Rosenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
3281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trembling P, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, et al.
BMC Public Health
. 2018 Mar;
18(1):409.
PMID: 29587697
Background: We investigated the association between self-reported skirt size (SS) and change in SS, and incidence of chronic liver disease (CLD) in a prospective cohort study of women recruited to...
2.
Trembling P, Lampertico P, Parkes J, Tanwar S, Vigano M, Facchetti F, et al.
J Viral Hepat
. 2014 Apr;
21(6):430-8.
PMID: 24750297
Assessment of liver fibrosis is important in determining prognosis, disease progression and need for treatment in patients with chronic hepatitis B (CHB). Limitations to the use of liver biopsy in...
3.
Wedemeyer H, Duberg A, Buti M, Rosenberg W, Frankova S, Esmat G, et al.
J Viral Hepat
. 2014 Apr;
21 Suppl 1:60-89.
PMID: 24713006
The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios:...
4.
Razavi H, Waked I, Sarrazin C, Myers R, Idilman R, Calinas F, et al.
J Viral Hepat
. 2014 Apr;
21 Suppl 1:34-59.
PMID: 24713005
The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections,...
5.
Bruggmann P, Berg T, Ovrehus A, Moreno C, Brandao Mello C, Roudot-Thoraval F, et al.
J Viral Hepat
. 2014 Apr;
21 Suppl 1:5-33.
PMID: 24713004
Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and...
6.
Rosenberg W, Tanwar S, Trembling P
QJM
. 2013 Sep;
107(1):17-9.
PMID: 24065837
The availability of the direct-acting antiviral agents (DAAs) boceprevir and telaprevir provides improved treatment outcomes for many patients infected with hepatitis C virus (HCV) genotype 1. However, HCV infection must...
7.
Guha I, Rosenberg W
Clin Liver Dis
. 2008 Nov;
12(4):883-900, x.
PMID: 18984472
Liver fibrosis is a common pathway of injury after chronic insult to the liver. The evolution of liver fibrosis to cirrhosis has many clinical implications, including bleeding, infection, hepatocellular carcinoma,...
8.
Cooper K, Bryant J, Picot J, Clegg A, Roderick P, Rosenberg W, et al.
QJM
. 2008 Jun;
101(8):631-41.
PMID: 18522976
Background: New techniques for diagnosing hereditary haemochromatosis (HHC) have become available alongside traditional tests such as liver biopsy and serum iron studies. Aim: To evaluate DNA tests in people suspected...
9.
Macdonald A, Libri N, Lustigman S, Barker S, Whelan M, Semper A, et al.
Clin Exp Immunol
. 2008 Mar;
152(2):265-73.
PMID: 18341617
We have described previously an immunostimulant derived from Onchocerca volvulus, the helminth parasite that causes onchocerciasis. Recombinant O. volvulus activation-associated secreted protein-1 (rOv-ASP-1) was a potent adjuvant for antibody and...
10.
Guha I, Parkes J, Roderick P, Harris S, Rosenberg W
Gut
. 2006 Oct;
55(11):1650-60.
PMID: 17047111
The diagnosis of fibrosis within liver disease is important for prognosis, stratification for treatment, and monitoring of treatment efficacy. The rising incidence and prevalence of non-alcoholic fatty liver disease (NAFLD)...